50. Infectious Risks Associated with Alemtuzumab (Campath)

  1. Deepali Kumar MD, MSc, FRCPC and
  2. Atul Humar MD, MSc, FRCPC
  1. Steven D. Burdette MD, FIDSA

Published Online: 5 MAY 2011

DOI: 10.1002/9781444397949.ch50

The AST Handbook of Transplant Infections

The AST Handbook of Transplant Infections

How to Cite

Burdette, S. D. (2011) Infectious Risks Associated with Alemtuzumab (Campath), in The AST Handbook of Transplant Infections (eds D. Kumar and A. Humar), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444397949.ch50

Editor Information

  1. Transplant Infectious Diseases, University of Alberta, Edmonton, Canada

Author Information

  1. Infectious Diseases Fellowship, Miami Valley Hospital Transplant Program, WSU Boonshoft School of Medicine, Dayton, OH, USA

Publication History

  1. Published Online: 5 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470658277

Online ISBN: 9781444397949

SEARCH

Keywords:

  • infectious risks associated with alemtuzumab (Campath);
  • lymphoid depletion (and pan T-cell depletion) - decreasing global immune activity, lower anti-donor response;
  • impact on laboratory monitoring;
  • bacterial infections;
  • BK virus - due to prolonged CD4 lymphopenia;
  • EBV/PTLD - recent data, no increased risk in kidney or pancreas kidney;
  • HCV/HBV - data lacking regarding HBV infection progression, associated with alemtuzumab;
  • miscellaneous infections;
  • Pneumocystis - prolonged risk due to T-cell depletion;
  • MAC, Mycobacterium avium complex